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ABSTRACT
Objectives To investigate the combined association of 
obesity, diabetes mellitus (DM) and cardiovascular disease 
(CVD) with severe COVID-19 outcomes in adult and elderly 
inpatients.
Design Cross- sectional study based on registry data from 
Brazil’s influenza surveillance system.
Setting Public and private hospitals across Brazil.
Participants Eligible population included 21 942 
inpatients aged ≥20 years with positive reverse 
transcription- PCR test for SARS- CoV-2 until 9 June 2020.
Main outcome measures Severe COVID-19 outcomes were 
non- invasive and invasive mechanical ventilation use, intensive 
care unit (ICU) admission and death. Multivariate analyses were 
conducted separately for adults (20–59 years) and elders (≥60 
years) to test the combined association of obesity (without 
and with DM and/or CVD) and degrees of obesity with each 
outcome.
Results A sample of 8848 adults and 12 925 elders were 
included. Among adults, obesity with DM and/or CVD showed 
higher prevalence of invasive (prevalence ratio 3.76, 95% CI 
2.82 to 5.01) and non- invasive mechanical ventilation use 
(2.06, 1.58 to 2.69), ICU admission (1.60, 1.40 to 1.83) and 
death (1.79, 1.45 to 2.21) compared with the group without 
obesity, DM and CVD. In elders, obesity alone (without DM and 
CVD) had the highest prevalence of ICU admission (1.40, 1.07 
to 1.82) and death (1.67, 1.00 to 2.80). In both age groups, 
obesity alone and combined with DM and/or CVD showed 
higher prevalence in all outcomes than DM and/or CVD. A 
dose–response association was observed between obesity and 
death in adults: class I 1.32 (1.05 to 1.66), class II 1.41 (1.06 to 
1.87) and class III 1.77 (1.35 to 2.33).
Conclusions The combined association of obesity, diabetes 
and/or CVD with severe COVID-19 outcomes may be stronger 
in adults than in elders. Obesity alone and combined with DM 
and/or CVD had more impact on the risk of COVID-19 severity 
than DM and/or CVD in both age groups. The study also 
supports an independent relationship of obesity with severe 
outcomes, including a dose–response association between 
degrees of obesity and death in adults.
INTRODUCTION
The COVID-19 pandemic, caused by the 
SARS- CoV-2, as of 11 July 2021, has already 
Strengths and limitations of this study
 ► This is the first study that describes the independent 
and combined relationship of obesity with COVID-19 
severity in Brazil, one of the biggest epicentres of 
the pandemic worldwide.
 ► The study was based on registry data of a large na-
tionwide sample of patients admitted, due to severe 
SARS- CoV-2 infection, to public and private hospi-
tals across the country.
 ► The large sample size and data availability allowed 
us to analyse the combined association of obesity, 
diabetes and cardiovascular disease with severe 
COVID-19 outcomes, separately by age groups and 
controlled by important confounding variables, for 
example, underlying comorbidities.
 ► The cross- sectional study design does not allow 
causal inference, and generalisation of results must 
be taken with caution since only hospitalised cases 
of severe COVID-19 were included.
 ► As the study used routinely collected data, which 
have not been designed primarily for research 
purposes, they may bring well- known limitations 
related to missing, underestimation and potential 
misclassification.
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reached more than 185 million infected people and 
more than 4 million deaths in all continents.1 Individ-
uals with advanced age and chronic diseases, including 
cardiometabolic diseases, are considered groups at major 
risk of complications and severe illness from COVID-19.2 3 
Obesity has been shown as an independent risk factor for 
COVID-19 disease.4–6 High body mass index (BMI) has 
been mentioned as a significant risk factor for COVID-
19, according to early clinical reports from China,7 Italy,8 
France,9 Mexico10 and the USA.11 Several studies have 
demonstrated that obesity is leading to considerably 
worse COVID-19 outcomes, especially greater risk of 
hospital and intensive care unit (ICU) admission, invasive 
mechanical ventilation and death.11–14
The COVID-19 pandemic is rapidly spreading world-
wide, especially in the Americas, where obesity is already a 
prevalent and important public health problem.15 16 Brazil 
is currently one of the biggest epicentres of the COVID-19 
pandemic worldwide, with more than 18.9 million cases 
and 528 000 deaths until 11 July 2021.1 In 2018, the prev-
alence of adult overweight and obesity in Brazil was esti-
mated at 55.7% and 19.8%, respectively.17 This obesogenic 
profile of the Brazilian population contributes, among 
other factors, to the high prevalence of obesity- related 
diseases, such as type 2 diabetes mellitus (DM) and 
cardiovascular diseases (CVDs), in the country.18 The 
fact that individuals with obesity also have more comor-
bidity diseases, which are either risk factors for COVID-19 
severity and death, makes obesity particularly ominous in 
COVID-19 disease.10–13
Several characteristics that can influence the clinical 
evolution of individuals infected with COVID-19, such 
as obesity, have been independently documented.5 6 19 
However, evidence is yet unclear on the combined effect 
that obesity and obesity- related comorbidities play in 
COVID-19 severity, especially, in different age groups. We 
aimed in this study to investigate the combined associa-
tion of obesity, diabetes, and CVD with mechanical venti-
lation use, ICU admission, and death in a large sample 
of adult and elderly patients hospitalised with COVID-19 
in Brazil. We also explored the independent association 
between degrees of obesity and the mentioned outcomes.
METHODS
Study design and population
This is a cross- sectional study based on registry data from 
SIVEP- Gripe (Influenza Epidemiological Surveillance 
Information System (Sistema de Informação de Vigilância 
Epidemiológica da Gripe)), an influenza surveillance 
system of Brazil’s Ministry of Health. The study used the 
publicly available dataset of SIVEP- Gripe, which includes 
de- identified data on cases of severe acute respiratory 
syndrome across public and private hospitals in Brazil.20 
These data were obtained through the Rede CoVida’s 
integrated data platform that has been built with official, 
open and authorised data for the production of knowl-
edge about the COVID-19 pandemic.
Our study population was composed of patients aged 
20 years or older, hospitalised for severe acute respiratory 
syndrome, with positive reverse transcription (RT)- PCR 
test for SARS- CoV-2 and final diagnosis of COVID-19 until 
9 June 2020. Only cases with complete data on demo-
graphic characteristics and comorbidities and plausible 
BMI values were included in the study.
Exposure variable
Obesity was defined as BMI equal to or greater than 30 
kg/m2, according to the cut- off points proposed by the 
WHO21 and the Pan American Health Organization22 
for adults and elders, respectively. BMI was calculated 
by health professionals in the hospital from directly 
measured or patient self- reported height and weight. 
Guidelines for the collection and analysis of anthropo-
metric data in health services have been previously stan-
dardised by the Ministry of Health.23 BMI values <12 or 
>70 kg/m2 were considered implausible and excluded.24 
Because BMI in the SIVEP- Gripe is mandatory and 
complete information for patients diagnosed or self- 
reported with obesity only, the nutritional status of all 
patients was confirmed by a dichotomous variable (no/
yes) on the existence of obesity available in the dataset. 
Likewise, information on the existence of diabetes and 
any chronic CVD was obtained from dichotomous ques-
tions (no/yes), which were answered based on patient or 
family’s report or medical diagnosis.
We created a polytomous four- category variable to 
evaluate the separate and combined exposure of obesity, 
diabetes and CVD: none/reference (no existence of 
obesity, diabetes and CVD), obesity (only existence of 
obesity),  obesity+DM and/or CVD (existence of obesity 
with diabetes and/or CVD), and DM and/or CVD (exis-
tence of diabetes and/or CVD). We also analysed obesity 
in adults according to the following degrees of severity 
based on WHO reference21: no obesity (<30 kg/m2), 
obesity class I (≥30–34.9 kg/m2), obesity class II (≥35–
39.9 kg/m2) and obesity class III (≥40 kg/m2). Due to the 
unavailability of BMI cut- off points to classify the degree 
of obesity in elders, this analysis was only performed for 
adults.
Outcome variables
The severe COVID-19 outcomes were mechanical venti-
lation use, ICU admission and death. Information on the 
use of mechanical ventilation by the patient was obtained 
and analysed as a polytomous three- category variable 
(no use/use of non- invasive ventilation/ use of invasive 
ventilation). ICU admission was obtained and analysed as 
a dichotomous variable (no/yes). Death was analysed as 
a dichotomous variable based on the patient’s endpoint 
outcome (cure/death).
Covariates
Demographic and comorbidity information was selected 
as descriptive and confounding variables.2 Age in years 
was calculated from birth and notification dates. Sex was 
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obtained as a dichotomous variable (female/male). The 
pre- existence of each comorbidity was also obtained as 
a dichotomous variable (no/yes): chronic pulmonary 
disease, asthma, chronic kidney disease, chronic haema-
tological disease, neurological disease, chronic liver 
disease and immunodeficiency/immunosuppression.
Statistical analysis
All analyses were subdivided into adults (≥20 and <60 
years) and elders (≥60 years). For descriptive analyses, 
absolute and relative frequencies were calculated for the 
demographic and comorbidity variables according to the 
main exposure variable. Multinomial logistic regression 
models were conducted to test the association of obesity 
(without and with diabetes and/or CVD) with non- 
invasive and invasive mechanical ventilation use. To test 
the association of this exposure variable with ICU admis-
sion and death, simple logistic regression models were 
performed. Same models were analysed considering the 
degree of obesity as the main exposure variable for adults. 
Given the high prevalence of the analysed outcome 
that could overestimate OR,25 crude and adjusted esti-
mates were interpreted based on the prevalence ratio 
(PR) and 95% CIs. These estimates were obtained from 
logistic models using delta method, function ‘prLogistic-
Delta’, which is implemented in R and available in the 
package ‘prLogistic’. Adjusted models included a set of 
confounding variables selected according to the current 
literature on obesity and severe COVID-9 risk factors26 27: 
sex, age (years), and the pre- existence of chronic pulmo-
nary disease, asthma, kidney disease, haematological 
disease, neurological disease, liver disease and immu-
nodeficiency/immunosuppression. The models that 
tested the degrees of obesity were also adjusted for DM 
and CVD. All analyses were performed using Stata V.15.1 
(Stata Corporation, College Station, USA) and R V.3.6.1 
(R Foundation for Statistical Computing, Austria).
Sensitivity analysis
Due the lack of detailed information on the comorbid-
ities (eg, duration, severity), serious comorbidities such 
as chronic pulmonary diseases and immunosuppression 
were tested as exclusion criteria instead of confounding 
variables in a sensitivity analysis. Same multivariate 
logistic models, using ‘death’ as outcome variable, were 
conducted separately for adults and elders, excluding the 
cases of pulmonary diseases and immunosuppression.
Patient and public involvement
As the study exclusively used publicly available de- iden-
tified data, it was not possible to involve patients or the 
public in the design, or conduct, or reporting, or dissem-
ination plans of our research.
RESULTS
During the study period, 21 942 individuals registered 
in the SIVEP- Gripe were ≥20 years old, hospitalised, 
tested positive for SARS- CoV-2, and had complete demo-
graphic and comorbidity information (figure 1). Of 
these, 169 (0.8%) were excluded due to implausible 
values of BMI. Of the 21 773 individuals included in the 
study, 8848 (40.3%) were adults aged between 20 and 59 
years, and 12 925 (59.6%) were elders aged 60 years or 
older. Since some patients were still hospitalised on the 
study endpoint date, information for some outcomes was 
incomplete. The study samples included in the analysis 
of each outcome were 8075 adults and 11 829 elders for 
mechanical ventilation, 8414 adults and 12 222 for ICU 
admission, and 6565 adults and 9943 elders for death. 
Figure 1 Selection of the study population from SIVEP- Gripe. BMI, body mass index; ICU, intensive care unit; SIVEP- Gripe, 
Influenza Epidemiological Surveillance Information System.
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Based on demographic and clinical characteristics, the 
analytical samples in each outcome were very similar to 
the overall study population and the excluded samples 
(online supplemental table 1).
The prevalence of obesity was 9.7% in adults and 3.5% 
in elders. The frequency of obesity without and with DM 
and/or CVD was, respectively, 4.6% and 5.1% in adults 
and 0.7% and 2.8% in elders. Non- invasive and inva-
sive mechanical ventilation was, respectively, required 
by 45.0% and 21.2% of adults and 47.0% and 30.0% of 
elders. ICU admission was needed by 35.4% of adults and 
43.6% of elders. Death occurred in 31.1% of adult and 
63.0% of elderly patients (tables 1 and 2).
In the adjusted analyses for adults, obesity alone 
(without DM and CVD) was associated with an increased 
prevalence of invasive (PR 2.69, 95% CI 1.98 to 3.65) 
and non- invasive mechanical ventilation need (PR 2.13, 
95% CI 1.64 to 2.78), ICU admission (PR 1.31, 95% CI 
1.13 to 1.53), and death (PR 1.33, 95% CI 1.05 to 1.69) 
when compared with the group without obesity, DM, and 
CVD. Obesity with DM and/or CVD was associated with 
an even higher prevalence of invasive mechanical venti-
lation (PR 3.76, 95% CI 2.82 to 5.01) and non- invasive 
ventilation use (PR 2.06, 95% CI 1.58 to 2.69), ICU admis-
sion (PR 1.60, 95% CI 1.40 to 1.83) and death in adults 
(PR 1.79, 95% CI 1.45 to 2.21). The subgroup of adults 
with DM and/or CVD showed in general lower PRs for all 
analysed outcomes than the subgroups with the presence 
of obesity alone or combined (table 3).
Among elders, obesity without DM and CVD was inde-
pendently associated with a higher prevalence of ICU 
admission (PR 1.40, 95% CI 1.07 to 1.82) and death (PR 
1.67, 95% CI 1.00 to 2.80). To a lesser extent, obesity with 
DM and/or CVD was also associated with an increased 
prevalence of invasive mechanical ventilation need (PR 
1.66, 95% CI 1.22 to 2.27), ICU admission (PR 1.37, 
95% CI 1.19 to 1.59) and death (PR 1.39, 95% CI 1.07 to 
1.80). Elders with DM and/or CVD had lower PRs for the 
analysed outcomes than the group of elders with obesity 
alone or combined (table 3).
In the analyses by the degree of obesity, we did not 
observe much difference in the prevalence of adverse 
outcomes, except for the prevalence of death that 
increased with the severity of obesity: class I 1.32 (95% CI 
1.05 to 1.66), class II 1.41 (1.06 to 1.87) and class III 1.77 
(1.35 to 2.33) (table 4).
The sensitivity analysis, excluding the cases of chronic 
pulmonary diseases and immunosuppression (online 
supplemental tables 2 and 3), showed no difference in 
the results when compared with the estimates described 
above which were instead adjusted for these comorbidi-
ties. Only small differences in the magnitude of the asso-
ciations, but not in the direction and significance, were 
observed.
DISCUSSION
This is the first study that describe the relationship 
of obesity and COVID-19 in Brazil, based on a large 
nationwide sample of adults and elders tested positive for 
SARS- CoV-2 and admitted to public and private hospitals. 
Our results highlight that obesity with DM and/or CVD 
was associated with higher rates of invasive mechanical 
ventilation use, ICU admission and death in adults, while 
obesity alone (without DM and CVD) was associated with 
higher rates of ICU admission and death among elders. 
In both age groups, obesity alone and obesity combined 
with DM and/or CVD had more impact on the risk of all 
severe COVID-19 outcomes than the subgroup with DM 
and/or CVD. The study also supports the independent 
association of obesity with the analysed outcomes and a 
dose–response association between degrees of obesity 
and death in adults.
Some mechanisms related to the role of obesity and 
related diseases in the worsening clinical condition of 
patients affected by SARS- CoV-2 have been pointed out: 
(1) greater body weight causes less elasticity of the chest 
wall and less total compliance of the respiratory system, 
leading to a restriction of the ventilation and the excur-
sion of the diaphragm, making the airway management 
in patients with obesity difficult28; (2) obesity is associ-
ated with sleep apnoea syndrome and chronic obstructive 
pulmonary disease, which lead to surfactant dysfunction 
and impede the proper functioning of the airways29; (3) 
obesity is a metabolic and inflammatory disease, which 
is associated with the development or worsening of 
other chronic and endocrine comorbidities (eg, type 2 
diabetes, hypertension, dyslipidaemia and CVD) that can 
modify innate and adaptive immune responses, making 
the immune system more vulnerable to infections and 
less responsive to antivirals and antimicrobial drugs16; 
(4) glycaemic decompensation, common in patients with 
obesity, is associated with impaired ventilation function.29
It is important to note that the COVID-19 pandemic 
imposes a double burden of disease, especially among 
the elderly individuals, since the prevalence of diabetes, 
hypertension, CVDs and other comorbidities associated 
with COVID-19 severity increases with age.3 30 However, 
our study suggests that obesity combined with diabetes 
and/or CVD may offer higher risk of COVID-19 severity 
for adults, although the overall prevalence of diseases 
and rates of ICU admission and mortality were higher 
in elders. Obesity alone seemed to provide higher risk 
of severe outcomes, especially death, in elders. As 1.00 
remains a plausible value for the PR, according to its CIs, 
we cannot conclude that the association of obesity alone 
with death in elders is clinically relevant. A larger sample 
would be needed to fully address this more.
Few studies to date have explored the combined and 
additional effect of obesity on COVID-19 severity.13 31 A 
study investigated the patterns of multimorbidity among 
fatal cases of COVID-19 in Colombia.31 Similar to our 
study, the authors found that obesity alone or with other 
diseases was associated with a higher risk of COVID-19 
fatality among young people. Furthermore, a population- 
based study in Mexico observed that the addition of 
obesity to any number of comorbidities significantly 
5Silva NdJ, et al. BMJ Open 2021;11:e050739. doi:10.1136/bmjopen-2021-050739
Open access
increased the risk of COVID-19 lethality.13 Using a caus-
ally ordered mediation analysis, this study also found that 
49.5% of the effect of diabetes on COVID-19 lethality was 
mediated by obesity, particularly in early- onset cases <40 
years of age.
Other studies also suggest that obesity is independently 
associated with severe outcomes of COVID-19, regardless 
of age and other associated comorbidities.11–14 A large 
study in Mexico13 showed that patients with obesity had 
higher rates of ICU admission and were more likely to 
Table 1 Demographic characteristics, comorbidities, hospitalisation outcomes and death according to the combined 
exposure of obesity (OB), diabetes mellitus (DM), and/or cardiovascular diseases (CVDs) in adults with severe COVID-19
Total None OB OB +DM and/or CVD DM and/or CVD
n % n % n % n % n %
Overall 8848 100.0 3161 35.7 409 4.6 452 5.1 4826 54.6
Sex
  Female 3774 42.7 1511 40.0 165 4.4 199 5.3 1899 50.3
  Male 5074 57.4 1650 32.5 244 4.8 253 5.0 2927 57.7
Age
  <40 years 1976 22.3 1064 53.9 188 9.5 102 5.2 622 31.5
  ≥40 years 6872 77.7 2097 30.5 221 3.2 350 5.1 4204 61.2
Chronic pulmonary disease
  No 8502 96.1 2969 34.9 388 4.6 435 5.1 4710 55.4
  Yes 346 3.9 192 55.5 21 6.1 17 4.9 116 33.5
Asthma
  No 8184 92.5 2728 33.3 383 4.7 414 5.1 4659 56.9
  Yes 664 7.5 433 65.2 26 3.9 38 5.7 167 25.2
Chronic kidney disease
  No 8297 93.8 2958 35.7 399 4.8 434 5.2 4506 54.3
  Yes 551 6.2 203 36.8 10 1.8 18 3.3 320 58.1
Chronic haematological disease
  No 8710 98.4 3081 35.4 406 4.7 445 5.1 4778 54.9
  Yes 138 1.6 80 58.0 3 2.2 7 5.1 48 34.8
Chronic neurological disease
  No 8588 97.1 3014 35.1 406 4.7 442 5.2 4726 55.0
  Yes 260 2.9 147 56.5 3 1.2 10 3.9 100 38.5
Chronic liver disease
  No 8684 98.2 3083 35.5 406 4.7 443 5.1 4752 54.7
  Yes 164 1.9 78 47.6 3 1.8 9 5.5 74 45.1
Immunosuppression
  No 8276 93.5 2777 33.6 393 4.8 440 5.3 4666 56.4
  Yes 572 6.5 384 67.1 16 2.8 12 2.1 160 28.0
Mechanical ventilation*
  No 2727 33.8 1144 42.0 93 3.4 88 3.2 1402 51.4
  Non- invasive 3634 45.0 1178 32.4 192 5.3 190 5.2 2074 57.1
  Invasive 1714 21.2 529 30.9 101 5.9 150 8.8 934 54.5
ICU admission*
  No 5438 64.6 2025 37.2 235 4.3 222 4.1 2956 54.4
  Yes 2976 35.4 1007 33.8 163 5.5 216 7.3 1590 53.4
Death*
  No 4525 68.9 1699 37.6 211 4.7 200 4.4 2415 53.4
  Yes 2040 31.1 640 31.4 92 4.5 140 6.9 1168 57.3
OB (BMI ≥30 kg/m2).
*Mechanical ventilation (n=8075), ICU admission (n=8414) and death (n=6565).
BMI, body mass index; DM, diabetes mellitus; ICU, intensive care unit.
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be intubated in relation to patients without obesity. This 
study also found a fivefold increased risk of mortality 
due to COVID-19 in patients with obesity.13 In a hospital- 
based study in France, it was observed that BMI >35 kg/
m2 was associated with the need for invasive mechanical 
ventilation.14
Few studies to date have similarly found a dose–
response association between degrees of obesity and 
Table 2 Demographic characteristics, comorbidities, hospitalisation outcomes and death according to the combined 
exposure of obesity (OB), diabetes mellitus (DM), and/or cardiovascular diseases (CVDs) in elders with severe COVID-19
Total None OB OB +DM and/or CVD DM and/or CVD
n % n % n % n % n %
Overall 12 925 100.0 2837 21.9 91 0.7 358 2.8 9639 74.6
Sex
  Female 5968 46.2 1232 20.6 52 0.9 209 3.5 4475 75.0
  Male 6957 53.8 1605 23.1 39 0.6 149 2.1 5164 74.2
Age
  <80 years 9355 72.4 2011 21.5 77 0.8 309 3.3 6958 74.4
  ≥80 years 3570 27.6 826 23.1 14 0.4 49 1.4 2681 75.1
Chronic pulmonary disease
  No 11 885 92.0 2494 21.0 85 0.7 325 2.7 8981 75.6
  Yes 1040 8.1 343 33.0 6 0.6 33 3.2 658 63.3
Asthma
  No 12 474 96.5 2687 21.5 90 0.7 336 2.7 9361 75.0
  Yes 451 3.5 150 33.3 1 0.2 22 4.9 278 61.6
Chronic kidney disease
  No 11 882 91.9 2608 22.0 85 0.7 311 2.6 8878 74.7
  Yes 1043 8.1 229 22.0 6 0.6 47 4.5 761 73.0
Chronic haematological disease
  No 12 728 98.5 2751 21.6 91 0.7 354 2.8 9532 74.9
  Yes 197 1.5 86 43.7 0 0.0 4 2.0 107 54.3
Chronic neurological disease
  No 11 871 91.9 2511 21.2 89 0.8 338 2.9 8933 75.3
  Yes 1054 8.2 326 30.9 2 0.2 20 1.9 706 67.0
Chronic liver disease
  No 12 734 98.5 2777 21.8 87 0.7 353 2.8 9517 74.7
  Yes 191 1.5 60 31.4 4 2.1 5 2.6 122 63.9
Immunosuppression
  No 12 303 95.2 2558 20.8 87 0.7 342 2.8 9316 75.7
  Yes 622 4.8 279 44.9 4 0.6 16 2.6 323 51.9
Mechanical ventilation*
  No 2725 23.0 626 23.0 18 0.7 70 2.6 2011 73.8
  Non- invasive 5557 47.0 1164 21.0 38 0.7 141 2.5 4214 75.8
  Invasive 3547 30.0 767 21.6 29 0.8 133 3.8 2618 73.8
ICU admission*
  No 6898 56.4 1578 22.9 41 0.6 168 2.4 5111 74.1
  Yes 5324 43.6 1107 20.8 44 0.8 181 3.4 3992 75.0
Death*
  No 3684 37.1 823 22.3 21 0.6 95 2.6 2745 74.5
  Yes 6259 63.0 1407 22.5 43 0.7 173 2.8 4636 74.1
OB (BMI ≥30 kg/m2).
*Mechanical ventilation (n=11 829), ICU admission (n=12 222) and death (n=9943).
BMI, body mass index; DM, diabetes mellitus; ICU, intensive care unit.
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COVID-19 death.32 Based on care records of 17 278 392 
UK adults, the study showed that the risk of COVID-19 
death increases independently with the degree of 
obesity: 30–34.9 kg/m2 (HR 1.05), 35–39.9 kg/m2 (1.40) 
and ≥40 kg/m2 (2.66).32 Other studies have evidenced 
the association of obesity with COVID-19 complications 
and death among adults.12 33 A hospital- based study in 
New York City showed that morbid obesity (BMI ≥40 kg/
m2) is strongly and independently associated with death 
in hospitalised patients younger than 50 years.33 Another 
study in New York City found a similar dose–response rela-
tionship between degrees of obesity and acute and critical 
care.12 Patients less than 60 years old with BMI between 
30 and 34.9 kg/m2 (obesity class I) were 2.0 and 1.8 
times more likely to be admitted for acute care (general 
hospital admission) and critical care (ICU admission or 
invasive ventilator), respectively, compared with individ-
uals with BMI <30 kg/m2. Patients of the same age group 
with BMI ≥35 kg/m2 (obesity class II and III) showed 2.2 
and 3.6 more chances of being hospitalised for acute and 
critical care, respectively.12
Strengths and limitations
One of the greatest strengths of the study was the use of 
SIVEP- Gripe dataset. Because severe acute respiratory 
syndrome is a condition of compulsory notification in 
both public and private hospitals,34 we have a nationwide 
representative sample of patients hospitalised for severe 
COVID-19 in Brazil. In addition, the large sample sizes 
allowed us to analyse adults and elders separately, as well 
as the degrees of obesity which dose–response association 
with death was evidenced. The availability of important 
confounding variables (sex, age and pre- existing comor-
bidities) to control the estimated associations, as well as 
hospital outcomes and mortality of COVID-19, was another 
differential of the study. Only patients with positive RT- PCR 
test for SARS- CoV-2 and final diagnosis for COVID-19 were 
included which gives greater precision on the studied 
population. The availability and use of data from health 
surveillance systems may be a lesson from Brazil that other 
countries can learn for obtaining routine and timely data 
to guide health systems and research in preparing and 
responding to pandemics before and during their course.
Table 3 Combined association of obesity (OB), diabetes mellitus (DM), and/or cardiovascular disease (CVD) with non- 
invasive and invasive mechanical ventilation use, intensive care unit (ICU) admission, and death in adult and elderly patients 
hospitalised with severe COVID-19
Main exposure 
variable
Non- invasive mechanical ventilation* Invasive mechanical ventilation*
Crude model Adjusted model† Crude model Adjusted model†
PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Adults 20–59 
years
None 1.00 1.00 1.00 1.00
OB 2.00 1.54 to 2.60 2.13 1.64 to 2.78 2.35 1.74 to 3.17 2.69 1.98 to 3.65
OB +DM and/or CVD 2.10 1.61 to 2.73 2.06 1.58 to 2.69 3.69 2.78 to 4.89 3.76 2.82 to 5.01
DM and/or CVD 1.44 1.29 to 1.60 1.35 1.20 to 1.51 1.44 1.26 to 1.64 1.32 1.14 to 1.52
Elders ≥60 
years
None 1.00 1.00 1.00 1.00
OB 1.14 0.64 to 2.01 1.22 0.69 to 2.16 1.31 0.72 to 2.39 1.43 0.78 to 2.61
OB +DM and/or CVD 1.08 0.80 to 1.47 1.15 0.84 to 1.55 1.55 1.14 to 2.11 1.66 1.22 to 2.27
DM and/or CVD 1.13 1.01 to 1.26 1.14 1.01 to 1.27 1.06 0.94 to 1.20 1.10 0.97 to 1.24
ICU admission‡ Death§
Crude model Adjusted model† Crude model Adjusted model†
PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Adults 20–59 
years
None 1.00 1.00 1.00 1.00
OB 1.23 1.08 to 1.40 1.31 1.13 to 1.53 1.11 0.92 to 1.33 1.33 1.05 to 1.69
OB +DM and/or CVD 1.48 1.33 to 1.65 1.60 1.40 to 1.83 1.50 1.30 to 1.74 1.79 1.45 to 2.21
DM and/or CVD 1.05 0.99 to 1.12 1.03 0.95 to 1.12 1.19 1.10 to 1.29 1.16 1.03 to 1.30
Elders ≥60 
years
None 1.00 1.00 1.00 1.00
OB 1.26 1.02 to 1.55 1.40 1.07 to 1.82 1.06 0.89 to 1.27 1.67 1.00 to 2.80
OB +DM and/or CVD 1.26 1.13 to 1.41 1.37 1.19 to 1.59 1.02 0.93 to 1.12 1.39 1.07 to 1.80
DM and/or CVD 1.06 1.01 to 1.12 1.11 1.04 to 1.18 1.00 0.96 to 1.03 1.05 0.95 to 1.16
OB (BMI ≥30 kg/m2).
*Crude and adjusted multinomial logistic regression models for mechanical ventilation use in adults (n=8075) and elders (n=11 829).
†Adjusted for sex, age in years, pulmonary disease, asthma, kidney disease, haematological disease, neurological disease, liver disease and 
immunosuppression.
‡Crude and adjusted logistic regression models for ICU admission in adults (n=8414) and elders (n=12 222).
§Crude and adjusted logistic regression models for death in adults (n=6565) and elders (n=9943).
BMI, body mass index; DM, diabetes mellitus; PR, prevalence ratio.
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The study also has some limitations that must be consid-
ered. Because this is a cross- sectional study, a causal asso-
ciation cannot be inferred. As we used routinely collected 
data, which have not been designed primarily for research 
purposes, they may bring well- known limitations related 
to missing, underestimation and potential misclassi-
fication. Obesity prevalence may have been underes-
timated due to the completeness of obesity and BMI 
data. Previous studies using SIVEP- Gripe data have also 
found a low prevalence of obesity in this population.35 36 
Better routine collection of height and weight data is still 
needed in clinical practice. Also, we believe that health 
professionals have adopted more the one method to 
collect weight and height information for BMI calcula-
tion, such as the patient’s self- report and direct measure. 
Therefore, in addition to BMI which implausible values 
were checked and excluded, the classification of obesity 
was also confirmed from a dichotomous variable on the 
presence of obesity (no/yes). Although it is known that 
BMI does not distinguish between fat and lean body mass, 
and thus may lead to misclassification bias, BMI has been 
shown as a strong predictor of excess body fat and has 
been widely used in epidemiological studies.15 Informa-
tion for some outcomes was incomplete because some 
patients were still hospitalised on the study endpoint 
date. However, that did not represent a potential selec-
tion bias to our study. The analytical samples in each 
outcome had similar demographic and clinical charac-
teristics to the overall study population and the excluded 
samples (online supplemental table 1). As information 
on smoking was not available and ethnicity/race was very 
incomplete in the SIVEP- Gripe dataset, they were not 
included in the analysis. Additional studies are needed 
to further explore the relationship between obesity and 
severe COVID-19, considering health risk behaviours and 
socioeconomic characteristics. Finally, the generalisa-
tion of results must be taken with caution since the study 
included only hospitalised cases of COVID-19.
CONCLUSIONS
The combined association of obesity, diabetes, and/or 
cardiovascular disease with severe COVID-19 outcomes, 
especially ICU admission and death, may be stronger in 
adult than in elderly inpatients. In both age groups, obesity 
alone and obesity combined with DM and/or CVD had 
more impact on the risk of all severe COVID-19 outcomes 
than the subgroup with DM and/or CVD. The study also 
supports an independent relationship of obesity with the 
severe outcomes, including a dose–response association 
between degrees of obesity and death in adults. These 
findings suggest important implications for the clinical 
care of patients with obesity and severe COVID-19, such 
as the increased need of critical care and higher risk of 
death among these patients. Our study also supports the 
inclusion of people with obesity, independently of other 
pre- existing comorbidities and age, in the high- risk and 
vaccine- priority groups for protection from SARS- CoV-2 
infection.
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